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We have recently shown that tubular form of rotavirus (RV) recombinant VP6 protein has an in vivo adjuvant effect on the
immunogenicity of norovirus (NoV) virus-like particle (VLP) vaccine candidate. In here, we investigated in vitro effect of VP6
on antigen presenting cell (APC) activation and maturation and whether VP6 facilitates NoV VLP uptake by these APCs. Mouse
macrophage cell line RAW 264.7 and dendritic cell line JAWSII were used as model APCs. Internalization of VP6, cell surface
expression of CD40, CD80, CD86, and major histocompatibility class II molecules, and cytokine and chemokine production
were analyzed. VP6 nanotubes were efficiently internalized by APCs. VP6 upregulated the expression of cell surface activation
and maturation molecules and induced secretion of several proinflammatory cytokines and chemokines. The mechanism of
VP6 action was shown to be partially dependent on lipid raft-mediated endocytic pathway as shown by methyl-𝛽-cyclodextrin
inhibition on tumor necrosis factor 𝛼 secretion. These findings add to the understanding of mechanism by which VP6 exerts its
immunostimulatory and immunomodulatory actions and further support its use as a part of nonlive RV-NoV combination vaccine.
1. Introduction
Noroviruses (NoVs) and rotaviruses (RVs) are the major
causative agents of pediatric acute gastroenteritis (AGE) in
children worldwide. There is no licensed vaccine for NoV
available, and despite efficacious live RV vaccines currently
in use [1], there is a need [2] for nonlive RV vaccines that
could be safer [3], more affordable, and more efficacious
in developing countries [4–6]. Our group has developed a
subunit combination vaccine candidate against NoV and RV
gastroenteritis, consisting of NoV virus-like particles (VLPs)
and RV VP6, aiming to confer protection from both leading
etiological agents of severe AGE [7–9].
The double-stranded (ds) RNA genome of triple-layered
RV particle is surrounded by core protein VP2 [10]. The out-
ermost layer, composed of VP7 capsid glycoprotein and the
spike proteinVP4, containsmost epitopes forRVneutralizing
antibody interaction [11]. The intermediate layer is formed
by the major internal structural protein VP6 that represents
51% of the virion mass [12]. VP6 trimers are organized
into hexagons and packed into higher order structures, for
example, nanotubes, nanospheres, or sheets when expressed
in vitro in baculovirus (BV) or bacterial expression systems
[12–16]. The variable morphology of polymeric VP6 protein
expressed in vitro depends on biochemical composition,
mainly on pH and ionic strength [17].
Recombinant VP6 has been considered as a nonlive next
generation vaccine candidate against RV by us and others,
being the most abundant, highly conserved, and immu-
nogenic RV protein [2, 7, 8, 18]. B-cell-mediated immune
responses, especially IgA seroconversion following RV vac-
cination and natural infection, are mostly directed against
VP6 [19]. Even though the inner capsid protein VP6 cannot
elicit classical neutralizing antibodies, it induced heterotypic
protective immunity against live RV challenge in mice that
correlated with postchallenge VP6-specific serum IgA [20].
VP6-specific polymeric IgA inhibits RV replication intra-
cellularly during IgA transcytosis, a phenomenon termed
intracellular neutralization [21–23].
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We have recently reported that VP6 protein provides
dose sparing effect on NoV VLPs in vivo and acts as both
Th1 and Th2 type adjuvant on immune response induced by
NoV VLPs [24]. Other investigators have shown that when
VP6 is used as an antigen carrier or delivery platform for
foreign antigens, the response to the antigen was improved
[25, 26]; however, the mechanism was not investigated.
Particulate nature and characteristics of an antigen, such as
size, shape, surface charge, and receptor interactions, are
generally considered important for antigen presenting cell
(APC) targeting [27]. Moreover, the antigen size influences
development and quality of immune responses [28, 29]. Even
though VP6 nanotubes and RV double-layered (dl) 2/6-VLPs
have been shown to be equally immunogenic in vivo [30],
there have also been indications of improved uptake of VP6
nanotubes compared to spherical forms of RV dlVLP [31].
We hypothesized that due to their size and morphology
VP6nanotubesmay be potent inducers ofAPCactivation and
maturation. APCs are known to be critical for initiating and
modulating antigen-specific immune responses [32, 33] and
therefore are likely to have a key role in VP6 exerted adjuvant
effect [24, 31]. In here, we investigated the effect of VP6
nanotubes on two commonly used APC lines, RAW 264.7
macrophages and JAWSII immature dendritic cells (DCs),
aiming to improve understanding of the immunostimulatory
and immunomodulatory mechanism of VP6 oligomeric pro-
tein.
2. Materials and Methods
2.1. Cell Lines, Viruses, and Culture Conditions. Adherent
murine immortalized RAW 264.7 macrophage cell line,
originating from bloodmonocyte/macrophages (H-2d) (Cat.
TIB71), and JAWSII immature DCs, derived from bone
marrow of H-2b C57BL/6 p53-knockout mouse (Cat. CRL-
11904) [34], were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA). The cells were
grown at 37∘C in a 5% CO
2
air humidified atmosphere and
used for the treatments after at least 5 but less than 20
passages in our laboratory. RAW 264.7 cells were cultured
in Dulbecco’s modified Eagle’s minimum essential medium
(DMEM, Cat. D6546), supplemented with heat inactivated
10% fetal bovine serum (FBS, Cat. F9665), 100 units/mL peni-
cillin, 100 𝜇g/mL streptomycin (Cat. P0781), and 2mM L-
glutamine (Cat. G7513) (all from Sigma, St. Louis, MO). The
JAWSII cells were maintained inminimum essential medium
Eagle, alpha minimum essential medium (𝛼MEM) supple-
mented with ribonucleosides, deoxyribonucleosides (Cat.
M8042, Sigma), 1mM sodium pyruvate (Cat. S8636, Sigma),
20% FBS, 4mM L-glutamine, and 5 ng/mL recombinant
murine granulocyte-macrophage colony-stimulating factor
(GM-CSF, Cat. 415ML-010, R&D Systems, Inc.). Human
epithelial colorectal adenocarcinoma cell line Caco-2 (ATCC,
Cat. HTB-37) was used for internalization studies. Adherent
Caco-2 cell line was cultured in a complete culture medium
consisting of DMEM medium, 10% FBS, 100 units/mL peni-
cillin, and 100 𝜇g/mL streptomycin. Caco-2 cells were sub-
cultured when they reached ∼80% confluency and were not
allowed to form tight monolayer or to differentiate before
being used for the internalization analyses. Human RV strain
Wa (G1P1A [8]) was propagated in fetal rhesus monkey
kidney (MA104) cells as described elsewhere [30].
2.2. Recombinant Proteins Production and Purification.
Human RV VP6 protein (database accession number
GQ477131) and NoV GII.4 (reference strain accession
number AF080551) VLPs were produced in a BV-insect cell
expression system according to the previously described
procedures [7, 8, 35]. The proteins were highly purified with
demanding multistep chromatographic procedures [24] and
the concentration, purity, integrity, and morphology of the
proteins were verified as described in detail elsewhere [7, 24].
In brief, Pierce BCA protein assay (Thermo Scientific, Cat.
23227) was used for quantification of the total protein. The
integrity of RV VP6 nanotubes (Figure 1(a)), trimeric VP6
(Figure 1(b)), and NoV GII.4 VLPs (Figure 1(c)) was verified
under electron microscopy (EM). The purity was confirmed
by Quant-it dsDNA Broad-Range Assay Kit (Invitrogen, Cat.
Q33120; <10 ng dsDNA/10 𝜇g of protein) and sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
densitometric analysis after silver staining (PageSilver
silver staining kit, Fermentas, Cat. K0681) (data not
shown). Infectious BV and endotoxin level were determined
with BacPAK RapidTiter Kit (Clontech Laboratories,
Cat. 631406; 0 pfu live BV/mL) and Limulus Amebocyte
Lysate assay (Lonza, Cat. 244N184-25; <0.1 endotoxin
units/100 𝜇g of protein). Crude purified VP6 preparation
containing impurities related to the expression system,
for example, residual BVs (106 plaque forming units/mL),
was used in parallel with pure VP6 in internalization
inhibition experiments as described below. The proportion
of VP6 in impure VP6 preparation was calculated after
the densitometric analysis of PAGE with AlphaEase FC
Software (Alpha Innotech, San Leandro, CA), as described
previously [30].
2.3. Internalization of RV VP6, RV Wa, and GII.4 VLPs by
Cell Lines. Uptake of RV VP6 nanotubes and RV Wa was
tested in mouse RAW 264.7 macrophages, JAWSII DCs, and
human colorectal epithelial Caco-2 cell lines. Each cell line
was plated to cell-culture treated multidish wells and was
allowed to attach overnight in the cell-type-specific culture
medium.The culture mediumwas replaced with themedium
containing 100 𝜇g/mL of highly purified VP6 nanotubes,
1 : 10 diluted RV Wa, or fresh culture medium (for untreated
control cells). After the incubation period of 4 h for RAW
264.7 cells only or 24 h for all three cell types, the cells
were harvested and supernatants collected and stored at
−80∘C for cytokine analysis.The VP6 uptake was analyzed by
intracellular staining and flow cytometry as described below.
The internalization of NoV GII.4 VLPs and cointernal-
ization of GII.4 VLPs with RV VP6 nanotubes were carried
out using the RAW 264.7 cells and 24 h incubation. Cells
were pulsed with 100 𝜇g/mL GII.4 alone or 100 𝜇g/mL of
GII.4 combined with 100 𝜇g/mL of VP6. The internalization
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Figure 1: Structure and integrity of the proteins. Electron microscopy images of RV VP6 nanotubes (a), trimeric VP6 (b), and NoV GII.4
VLPs (c). Protein products were examined by FEI Tecnai F12 electron microscope (Philips Electron Optics, Holland) following negative
staining with 3% uranyl acetate, pH 4.6. Bar 100 nm. Images observed at 9300x (a and b) and 11,000x (c) magnification.
of GII.4 VLPs was analyzed by intracellular staining of NoV
VLP and flow cytometry.
2.4. Macrophage and DC Activation and Maturation Analysis.
VP6 mediated activation and maturation were explored
by determining the change in the expression of cell sur-
face markers and upregulation of cytokine secretion. After
overnight incubation of RAW or JAWSII cells on the
plates, the cell-culture medium was changed and cells were
exposed to RV VP6 nanotubes (10 𝜇g/mL or 50𝜇g/mL),
trimeric (denatured) VP6 (10𝜇g/mL or 50𝜇g/mL), GII.4
VLPs (10 𝜇g/mL or 50𝜇g/mL), RV Wa (1 : 10 dilution), or
1 𝜇g/mL of bacterial lipopolysaccharide (LPS) (Cat. L6143,
Sigma) and incubated further for 24 h or 48 h. Supernatants
of all cultures were collected, centrifuged, and stored at −80∘
until cytokine analysis. The cell surface expression of cos-
timulatory andmaturationmarkers CD80, CD86, CD40, and
major histocompatibility complex (MHC) class II molecules
was analyzed by flow cytometry as described below.
2.5. Inhibition of RV VP6 Internalization. Pharmacologi-
cal internalization inhibitorsmethyl-𝛽-cyclodextrin (M𝛽CD,
Cat. C4555), chloroquine diphosphate salt (Cat. C6628), and
cytochalasin D from Zygosporium mansonii (Cat. C2618) (all
from Sigma) were employed. RAW cells were plated and
allowed to attach before adding the inhibitors at predeter-
mined nontoxic concentrations. Cells were preincubated in
cell-culture medium supplemented with 15𝜇M chloroquine,
2mM M𝛽CD (without serum), or 2 𝜇M cytochalasin D for
60min before exposing cells to 50 𝜇g/mL of VP6 nanotubes
and incubating them further for 17 h. In addition, the con-
centration of 50𝜇g/mL of crude purified VP6 nanotubes
containing impurities related to the expression system, for
example, residual BVs, was used as a control.
2.6. Flow Cytometry Analysis. The cells were harvested and
washed with cold PBS + 3% FBS. Prior to staining or
permeabilization the cells were blocked with rat anti-mouse
CD16/CD32 (Fc Block, Clone 2.4G2, Becton Dickinson, San
Jose, CA) on ice for 10min followed by washing with PBS
+ 3% FBS. For intracellular staining of the internalized RV
VP6 or NoV GII.4 VLPs, the BD Cytofix/Cytoperm Plus
kit (Becton Dickinson, San Jose, CA) was used according to
manufacturer’s instructions. For detection of VP6, permeabi-
lized and fixed cells were stained intracellularly with rabbit
polyclonal rotavirus group A antibody (Cat. GWB-459FC9,
Genway Biotech Inc.) followed by fluorescein isothiocyanate-
(FITC-) conjugated goat anti-rabbit Ig (BDPharmingen). For
GII.4 VLP staining, a human serum highly positive for anti-
GII.4 NoV antibodies was used at 1 : 2000 dilution, followed
by polyclonal anti-human IgG (Fc 𝛾-specific) phycoerythrin
(PE) conjugate (eBioscience) for detection. Internalization
was examined by overlaying the histograms of treated and
untreated cells and by comparingmean fluorescence intensity
(MFI) of each population.
For the cell surface molecules expression analysis, RAW
264.7 cells were stained on ice for 30min with anti-mouse
monoclonal antibodies PerCP-Cy5.5-conjugated CD80 (16-
10A1), PE-Cy7-conjugatedCD86 (GL1), PE-conjugatedCD40
(3/23), and Alexa Fluor 647-conjugated I-A/I-E (M5/114.15.2)
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(mouse MHC class II). BD CompBeads used for com-
pensation and conjugated cell surface marker monoclonal
antibodies were purchased from BD Biosciences.
The flow cytometry analyses were performed on a FAC-
SCanto II (BectonDickinson, San Jose, CA) flow cytometer,
using the FACSDivaVersion 6.1.3 software (Becton Dickin-
son). The data analysis was carried out with FlowJo software
version 10 (Three Star Inc., San Carlos, CA).
2.7. Cytokine ELISAs. Quantities of tumor necrosis factor
alpha (TNF-𝛼), interleukin-6 (IL-6), and interferon-alpha
(IFN-𝛼) cytokines inRAWand JAWSII cell supernatantswere
determined by commercial enzyme-linked immunosorbent
assay (ELISA) kits: mouse TNF-𝛼 DuoSet (Cat. DY410-05),
mouse IL-6 DuoSet (Cat. DY406-05), and VeriKine mouse
IFN alpha ELISA kit (Cat. 42120-1, PBL Assay Science)
according to the manufacturers’ instructions. Victor2 1420
Multilabel Counter (Wallac, Perkin Elmer) plate reader was
used for optical density reading (OD) of the plate. For each
assay the background signal from the blank wells (wells
without supernatant) was subtracted from all of the OD
readings on the plate. Standard curves were plotted and used
for calculating the cytokine concentration of each sample
(pg/mL).
2.8. Cytokine Array. Cytokine antibody array was performed
with a mouse cytokine array kit (Cat. ARY006, R&D Sys-
tems, Inc., MN) according to the manufacturer’s protocol.
Briefly, RAW 264.7 cell-culture supernatants were collected
after 24 h stimulation with 100 𝜇g/mL VP6 nanotubes or
left untreated. Supernatants were centrifuged and stored
at −80∘C until analyzed. The membranes precoated with
40 different cytokine/chemokine-specific capture antibodies
were blocked and incubated with 1 : 5 diluted supernatants
overnight at +4∘C. After washing, the detection antibody
cocktail was added for 30min, followed by streptavidin-
horseradish peroxidase and chemiluminescent detection
reagent. The immunoblot images were captured and visu-
alized using a Bio-Rad ChemiDoc MP system and the
intensity of each spot in the captured images was analyzed
using a ImageJ 1.50b software.
2.9. Statistical Analysis. Cytokine release (pg/mL) in ELISA
was compared using Mann–Whitney 𝑈 test. The data were
analyzed by IBM SPSS Statistics software version 22.0 and
𝑝 value of <0.05 was considered statistically significant.
3. Results
3.1. Internalization of VP6 Nanotubes by Macrophages and
Immature DC. After incubating RAW 264.7, JAWSII, or
human colorectal epithelial Caco-2 cells with 100 𝜇g/mL of
VP6 or RVWa, the entry of the RV protein was examined by
flow cytometry and compared to cells incubated with culture
medium only (untreated cells). VP6 nanotubes were shown
to be internalized by macrophages (Figure 2(a)) and DC
(Figure 2(b)) but not by Caco-2 epithelial cells (Figure 2(c)).
Within 24 h of incubation of RAWcells withVP6, the RV-
specific intracellular staining increased by 202–256% (range
of percent increase of MFI for three independent experi-
ments) compared to untreated cells. A 120% increase was
observed in RAW cells exposed to RVWa (Figure 2(a)). VP6
entry to RAW cells was observed already at 4 h but at a much
lower quantity than after 24 h (data not shown). VP6 was also
internalized by JAWSII cells within 24 h incubation but less
efficiently than by RAW macrophages (Figure 2(b)). Com-
pared to untreated cells, VP6 treatment induced a moderate
49–60,9% increase in RV-specific intracellular staining. In
contrast to these results, a control cell line for internalization,
human colorectal epithelial Caco-2 cells highly susceptible
to RV infection [36], did not take up VP6 alone, but a 282–
311% increase in MFI was detected after RV Wa exposure
(Figure 2(c)).
3.2. Activation andMaturation Phenotype of APCs Induced by
VP6 Nanotubes. After 24 h and 48 h stimulation of RAW and
JAWSII cells with 50 𝜇g/mL of VP6 nanotubes, 1 : 10 diluted
RV Wa, or 1 𝜇g/mL of LPS, the change in the expression
of cell surface molecules CD80, CD86, CD40, and MHC
II was examined by flow cytometry. As shown in Figures
3(a) and 3(b), VP6 stimulation upregulated MFI of all four
markers compared to untreated RAW cells already in 24 h,
which further increased within 48 h. LPS, used as a positive
control, upregulated strongly all markers already within 24 h
as expected (Figure 3(b)). Viral control (RVWa) also induced
high surface marker upregulation similarly to LPS (Figures
3(a) and 3(b)). Similar pattern of cell surface molecules
expression upregulation with all three stimuli was observed
with JAWSII cells but the increases were not as prominent as
with the RAW cells (data not shown).
3.3. Effect of VP6 on Proinflammatory Cytokines and Chemok-
ine Secretion. After 24 h or 48 h incubation of RAW and
JAWSII cells with VP6 nanotubes, GII.4 VLPs, nonpolymeric
denatured VP6 (10𝜇g/mL and 50 𝜇g/mL each protein), RV
Wa, or LPS, supernatant was collected and TNF-𝛼, IL-6, and
IFN-𝛼were quantified by ELISA (Figure 4(a)). Nonpolymeric
trimeric VP6 lacking conformational structures (Figure 1(b))
was used as a control protein.
Both RAW and JAWSII cells secreted TNF-𝛼 in a dose-
response manner after 10 and 50 𝜇g/mL VP6 nanotube
exposure (Figure 4(a)). However, GII.4 VLP did not induce
considerable TNF-𝛼 in JAWS cells (74 ± 57 pg/mL, resp.)
as did VP6 nanotubes at the same concentration (713 ±
296 pg/mL). TNF-𝛼 production was significantly higher in
VP6 nanotube exposed cells in both RAW and JAWSII cells
compared to untreated cells (𝑝 < 0.05). These two cell
lines exhibited different cytokine expression profiles upon
stimulation, the primary cytokine secreted by RAW cells
being TNF-𝛼, while JAWSII DCs produced higher quantities
of IL-6 (Figure 4(a)). Interestingly, VP6 nanotubes and RV
Wa induced similar TNF-𝛼 secretion inRAWcells (𝑝 > 0.05),
but only VP6 stimulated significant production of TNF-𝛼 in
JAWSII cells. A tubular structure of VP6 was essential for the
stimulatory effect of the protein, as more TNF-𝛼was secreted
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Figure 2: Internalization of VP6 nanotubes. Flow cytometry analysis of VP6 uptake by RAW 264.7 macrophages (a), JAWSII DCs (b), and
human colorectal Caco-2 cells (c) after 24 h incubation in the presence of 100𝜇g/mL VP6. Cells exposed to rotavirus (RV)Wa and untreated
cells incubated in culture medium only served as controls. VP6 was detected by intracellular staining with rabbit anti-rotavirus antibody
followed by goat fluorescein isothiocyanate-conjugated anti-rabbit Ig antibody. Shown are overlaid histograms of cells exposed to VP6
nanotubes or RVWa and untreated cells of one representative experiment of three independent experiments performed. Mean fluorescence
intensity (MFI) values of each histogram are indicated.
after exposing RAW cells to 10𝜇g/mL (1756 ± 135 pg/mL) or
50𝜇g/mL (9224 ± 1409 pg/mL) of VP6 nanotubes, compared
to the equal concentrations of nonpolymeric VP6 control (411
± 75 and 539 ± 14 pg/mL, resp.).
The constitutive IL-6 secretion by JAWSII cells was
remarkably stimulated by VP6 nanotubes, whereas only
subtle changes were detected in the supernatants of the cells
incubated in the presence of GII.4 VLP (Figure 4(a)). RV
Wa had a moderate effect on IL-6 secretion by JAWSII cells,
whereas the positive control LPS elicited high IL-6 secretion.
Only small quantities of IL-6 were produced by RAW cells
stimulated with VP6 and RV Wa but not at all with GII.4
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Figure 3: Continued.
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CM VP6 % increase % increase LPS % increase
CD40 149 324 117 1180 692 1433 862
CD80 127 307 142 448 253 2489 1860
CD86 1228 2167 76 3696 201 4877 297
MHC II 170 380 124 830 388 1018 499
CM VP6 % increase Wa % increase LPS % increase
CD40 376 854 127 3930 945 1898 405
CD80 306 764 150 2048 569 2409 687
CD86 2957 6187 109 12692 329 17106 478
MHC II 211 686 225 2339 1009 1308 520
48h stimulation
Wa
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(b)
Figure 3: Effect of VP6 nanotubes on RAW 264.7 cell surface markers expression. The expression of CD40, CD80, CD86, and MHC class
II (I-A/I-E) was analyzed by flow cytometry after 24 h and 48 h incubation in the presence of 50 𝜇g/mL VP6, 1 : 10 diluted RV Wa, 1 𝜇g/mL
LPS, or culture media (CM) only. (a) Expression of the molecules on the cells in CM only and upregulation induced by VP6 and RVWa are
shown by overlaid histograms. The results are representative of three independent analyses done. (b) Table of mean fluorescence intensity
(MFI) values obtained from the histograms in Figure 3(a) of each cell surface marker after treatment with VP6, RV Wa, LPS, or untreated
cells.
VLPs. As expected, antiviral cytokine IFN-𝛼 secretion was
detected only after RV Wa stimulation in both cell lines but
not when exposed to protein products or LPS.
The cytokine profile of RAW supernatant stimulated
with 100 𝜇g/mL VP6 for 24 h was further examined by
cytokine array, indicating a strong activation of the cells
(Figures 4(b) and 4(c)). Several cytokines and chemokines
were upregulated (Figure 4(c)), including interferon gamma-
inducible protein (IP-10) and macrophage inflammatory
protein (MIP-) 1𝛼 and MIP-1𝛽, when compared to super-
natant of untreated cells (CM only). However, TNF-𝛼,
granulocyte-colony-stimulating factor (G-CSF), MIP-2, IL-
1ra, and RANTES were only detected in VP6 stimulated cells.
As IL-6 cytokine production by RAW cells at 24 h was not
detected by ELISA (Figure 4(a)) and it was not detected by
the cytokine array either, corroborating the findings (data not
shown).
3.4. Effect of Chemical Inhibitors on Internalization and
TNF-𝛼 Production. The effect of chemical inhibitors M𝛽CD,
cytochalasin D, and chloroquine on the VP6 nanotube
internalization and VP6-induced TNF-𝛼 secretion by RAW
264.7 cells was investigated. Both highly purified VP6
nanotubes and the VP6 nanotubes known to contain BV-
related impurities, which assumingly employ different entry
pathways into the cells, were used in these experiments.
After M𝛽CD treatment, a 22 ± 11% decrease in TNF-𝛼
secretion was observed in RAW cells stimulated with pure
VP6 (Figure 5), whereas M𝛽CD showed an increasing effect
(43 ± 2%) when impure VP6 was used. Other two chemical
inhibitors, cytochalasin D and chloroquine, did not decrease
TNF-𝛼 production in RAW cells induced by pure VP6
nanotubes. On the contrary, TNF-𝛼 production induced by
impure VP6 was almost completely blocked (94 ± 0.1%) by
chloroquine treatment (Figure 5), indicating that the two
protein preparations have different stimulatory mechanism.
This observationwas further supported by∼26% inhibition of
impure VP6 internalization by chloroquine treatment, while
the internalization of pure VP6 did not significantly change
with any of the treatments (data not shown).
3.5. Increased GII.4 VLP Uptake and APC Activation and
Maturation byVP6Nanotubes Codelivery. Thecoadministra-
tion of VP6 nanotubes with GII.4 VLPs improved uptake of
GII.4 VLPs to RAW 264.7 cells (Figure 6(a)). When RAW
cells were incubated for 24 h with 100 𝜇g/mL GII.4 VLPs,
47% of the cells were positive for NoV GII.4 when analyzed
by intracellular staining. Coadministration of GII.4 VLPs
with VP6 nanotubes further increased the number of NoV-
positive cells by 30% (from 47% to 61%, resp.). A twofold
increase in TNF-𝛼 secretion was observed in cells incubated
with GII.4 + VP6 combination (11490 ± 741 pg/mL), com-
pared to GII.4 VLPs alone (5761 ± 922 pg/mL) (Figure 6(b)),
indicating an additive effect of the two proteins on the
cytokine secretion. Furthermore, improved maturation of
RAW macrophages was achieved with coadministration, as
illustrated in Figure 6(c). NoVGII.4 VLPs +VP6 upregulated
cell surface molecules CD40, CD80, CD86, and MHC II
expression compared to GII.4 VLPs alone. Interestingly,
MHC II downregulation was repeatedly observed when
incubating RAW cells with GII.4 VLPs only.
4. Discussion
We have recently shown in vivo adjuvant effect of VP6
nanostructures on the immunogenicity of NoV VLPs [24],
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Figure 4: Cytokine production in the supernatants of RAW 264.7 and JAWSII cells. (a) The quantity (pg/mL) of TNF-𝛼, IL-6, and IFN-𝛼 in
the supernatants of RAW and JAWSII cells incubated for 24 h or 48 h with 10 𝜇g/mL and 50 𝜇g/mL of VP6 nanotubes, NoV GII.4 VLPs, or
nonpolymeric VP6. RV Wa, LPS, and culture media only (untreated cells) served as controls. Zero values indicate that the result was below
the lowest standard dilution of the assay (62.5 pg/mL for TNF-𝛼, 15.6 pg/mL for IL-6, and 12.5 pg/mL for IFN-𝛼). nt = not tested. Shown are
the mean values of analysis done at least twice with independent samples. (b) The mouse cytokine multiplex array analysis of RAW 264.7
supernatants after 24 h stimulation with VP6 nanotubes (100 𝜇g/mL) or fresh culture media (untreated cells). (c) The pixel densities ± SD of
the replicates for each visible spot on the arrays, calculated using ImageJ software and plotted.
where coadministration of VP6 nanotubes with suboptimal
doses of NoV GII.4 VLPs increased the level of type-
specific and cross-reactive NoV-specific immune responses.
Therefore, in the present work, we investigated the effect
of VP6 on activation and maturation of mouse RAW 264.7
macrophages and JAWSII immature DCs. Macrophages and
DCs are professional APCs with high endocytic capacity
known to be central for mounting effective T- and B-
cell immune responses to foreign antigens in vivo [37–40].
The results provide an insight into the mechanism of VP6
adjuvant action.
RAW and JAWSII cells were first tested for uptake of
VP6 in vitro. Extremely pure recombinant VP6 nanotubes
were efficiently internalized by the RAW macrophages and
to less extent by JAWSII DCs. Human epithelial Caco-2 cells
were used as a control cell line as, unlike APCs, they are
not efficient in uptake of larger particles but are susceptible
to human RV Wa infection [36]. Accordingly, no significant
uptake of VP6 was detected in Caco-2 cells, while RVs
were readily internalized. These results are congruent with
the report by Rodr´ıguez et al. [31], who showed that VP6
nanotubes were favorable for macrophage uptake.
Along with being internalized by macrophages and
immature DCs, VP6 nanotubes induced activation and mat-
uration of APCs by upregulating cell surface costimulatory
and antigen presenting molecules CD40, CD80, CD86, and
MHC II. Signaling through CD80 and/or CD86 on mature
APCs, which bind to CD28 on T cells [41, 42], is a key
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Figure 5: Effect of chemical inhibitors on VP6-induced TNF-𝛼
secretion by RAW 264.7 cells. The change in TNF-𝛼 production
(%) by pharmacological inhibitors M𝛽CD, cytochalasin D, or
chloroquine of cells stimulated with 50 𝜇g/mL pure or impure VP6
nanotubes for 17 h in the presence or absence of an inhibitor.
VP6-induced TNF-𝛼 production (pg/mL) without an inhibitor was
considered 100%. Shown are the mean values of two independent
analyses with standard deviations.
costimulatory pathway for antigen-specific T cell activation.
A bacterial activator LPS, a toll-like receptor (TLR) 4 agonist,
was used as a control stimulus, as it is well known that
it induces activation of APCs, including RAW 264.7 cells
[43, 44]. The RAW 264.7 and JAWSII activation state was
also determined by release of broad panel of cytokines and
chemokines. An increase in the expression pattern of cell
activationmarkers followingVP6 exposurewas accompanied
by increase in proinflammatory cytokine secretion, primarily
TNF-𝛼 by RAW cells and IL-6 by JAWSII cells. In RAW cells,
50 𝜇g/mL VP6 nanotubes induced TNF-𝛼 at a similar level
to RV Wa and GII.4 VLPs stimulation. Interestingly, only
VP6 nanotubes but not GII.4 VLPs or RV Wa stimulated
remarkably high TNF-𝛼 and IL-6 response in JAWSII DCs.
Consistent with this observation, Istrate et al. [45] reported
that even if RV dlVLPs were internalized by DCs, they could
not trigger their activation. A key proinflammatory cytokine,
TNF-𝛼, recruits and activates APCs at the site of inflamma-
tion (antigen delivery) and facilitates APC migration to the
lymph nodes [46], thereby improving the antigen uptake and
presentation toMHC I andMHC II restricted T cells. In addi-
tion, TNF-𝛼 and IL-6 have important roles in the generation
of B-cell functions like proliferation and antibody secretion
[47]. Overall, quantification of TNF-𝛼 and IL-6 showed that
VP6 nanotubes are more potent in inducing these cytokines
than NoV VLPs or RV. In addition, a nonpolymeric VP6
protein was not able to induce cytokine secretion near to the
VP6 nanotubes. These results underline the importance of
intact high order tubular structure conformation of VP6 in
activation of APCs.
Furthermore, changes in the levels of different cytokines
and chemokines were evaluated in untreated or VP6 stimu-
lated RAW264.7 cells by cytokine array.The results suggested
that VP6 induces multiple cytokines (TNF-𝛼, G-CSF, and IL-
1ra) and chemokines (IP-10, MIP-1𝛽, MIP-2, and RANTES)
secretion into the supernatants of stimulated cells. G-CSF is a
multifunctional cytokine [48] that is required for modulating
macrophage and DC responses [38] and T cell responses fol-
lowing antigen stimulation [49]. RANTES, IP-10, IL-8, MIP-
1𝛽, and monocyte chemoattractant protein-1 (MCP-1) have
been suggested to be the key host factors in gastrointestinal
immunity during RV infection [50, 51].
Employing highly purified protein preparations is of high
importance when investigating adjuvant properties of a pro-
tein, eliminating the immunostimulatory effect of impurities
related to the protein expression system on APCs.The results
with VLP preparations containing residual BV particles have
strongly suggested that BV contaminants can trigger an
innate immunity, inducing inflammatory cytokine produc-
tion such as TNF-𝛼, IL-6, and IFN-𝛼 [44, 52, 53]. Therefore,
we tested RAW264.7 and JAWSII cells for secretion of IFN-𝛼,
an antiviral cytokine induced upon live virus or virus-derived
dsRNA stimulation of the cells through TLR3 [45, 53, 54].
Only RVWa stimulation but not any other stimuli including
highly purified VP6 nanotubes, GII.4 VLP, or LPS induced
significant release of the cytokine by these cell lines showing
that the recombinant proteins used to stimulate the APC in
our assays were free of BV contamination.
The size from 0.2 𝜇m to 1.5 𝜇m and the morphology
of VP6 nanotubes are favorable for macrophages and DC
recognition and uptake resembling those of microorgan-
isms [30, 31, 55]. Antigen acquisition by APCs is mediated
by several uptake mechanisms such as receptor-mediated
endocytosis, macropinocytosis, and phagocytosis, depend-
ing of the nature of the antigen [56–59]. Smaller particles
(20–200 nm) are usually internalized via receptor-mediated
endocytosis dependent on membrane clathrin or caveolin
[60]. Larger particles are taken up by macrophages, B cells,
Langerhans cells, and DC, through receptor-independent
macropinocytosis (>0.5 𝜇m) or receptor-mediated phagocy-
tosis (0.5–5 𝜇m) [61]. Bluetongue virus nonstructural NS1
protein tubular structures, which are similar in size (up to
1 𝜇m long and app. 50 nm in diameter) and morphology
to VP6 nanotubes, were suggested to be internalized by
macrophages and DC via endocytosis and macropinocytosis
[62]. We used chemical inhibitors M𝛽CD, chloroquine, and
cytochalasin D to study the possible uptake and activation
pathways of VP6 nanotubes [63]. TNF-𝛼 secretion was used
for evaluating inflammatory APC activation and impure
VP6 preparation containing production related impurities,
including BV, was included as a control. Our results indicated
a difference in the mechanism of RAW 264.7 cells uptake
and activation by the two RV VP6 protein preparations.
M𝛽CD treatment depletes cholesterol which is a reversible
mechanism that inhibits the formation of cholesterol-rich
microdomains termed lipid rafts [64] important in the lipid
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Figure 6: Internalization and activating/maturating effect of NoV GII.4 VLPs alone or combined with RV VP6 nanotubes on RAW 264.7
cells. (a) Flow cytometry analysis of GII.4 VLPs uptake by RAW264.7 cells after 24 h incubation with 100𝜇g/mL of GII.4 VLPs alone ormixed
with 100𝜇g/mL of VP6 nanotubes.The intracellular staining of untreated cells (CM), GII.4 VLP treated cells, and GII.4 + VP6 treated cells, of
a representative experiment of two independent analyses, is shown. (b)The level of TNF-𝛼 in cell-culture supernatants as measured by ELISA
after 24 h incubation with 100𝜇g/mL of GII.4 VLPs alone, 100 𝜇g/mL VP6 alone, or GII.4 VLPs mixed with 100 𝜇g/mL of VP6 nanotubes.
Shown are the mean values and standard deviations of two independent analyses. (c)The expression of cell surface markers measured by flow
cytometry after 24 h stimulation. The results represent % increase or decrease of the MFI of each marker on the cells incubated with GII.4
VLPs alone or with combined GII.4 VLPs and VP6 nanotubes compared to baseline level of untreated cells. The mean values with standard
deviations of two independent analyses are presented.
raft-mediated endocytosis. Interestingly, when pure VP6
nanotubes were used, M𝛽CD partially inhibited TNF-𝛼
secretion (22%), whereas impure VP6-induced TNF-𝛼 secre-
tion was blocked almost completely by clathrin-dependent
endocytosis inhibitor chloroquine. In support to our findings,
Rodr´ıguez et al. [31] showed by fluorescent microscopy the
inhibition of VP6 cellular entry by M𝛽CD. Furthermore,
Abe et al. [53] observed that treatment with chloroquine
inhibited BV-induced innate immune system activation and
TNF-𝛼 secretion through BV gp64-mediated membrane
fusion and TLR9/MyD88-dependent pathway. Cytochalasin
D, which inhibits actin-dependent cellular processes such as
phagocytosis [65], was not observed to have an effect on
TNF-𝛼 secretion or VP6 protein uptake, unlike the pub-
lished results where BV expression system-derived human
immunodeficiency virus VLPs entry to APCs was blocked
[66]. Altogether, the results with chemical inhibitors indicate
that VP6 entry and activation of RAW cells require host
cholesterol and may be partially mediated by lipid rafts.
Due to the size range of VP6 nanotubes (∼0.2–1.5 𝜇m, [30]),
several entry pathways are likely to be involved and reaching
total blocking is challenging.
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Adjuvants generally work to spare the dose of particular
vaccine antigen, to broaden the immune responses, and to
prolong the duration of the response. The results of this
study support our earlier findings of VP6 adjuvant effect on
NoV VLPs immunogenicity in vivo [24] and show that VP6
nanotubes are efficiently internalized by APCs and induce
activation and maturation of APCs. Induction of proin-
flammatory cytokines and chemokines by VP6 stimulated
APCs, as shown in here, indicates efficient activation of
the innate immune system, a major mechanism of adjuvant
action. A depo effect is yet another important mechanism
of adjuvant action that facilitates and improves the uptake
of antigens by APCs. In here, a 30% increase in NoV GII.4
VLP uptake by APCs was observed when NoV VLPs were
codelivered with RV VP6, compared to GII.4 VLP alone. In
addition, VP6 coadministration showed increased activation
andmaturation of APCsmeasured by TNF-𝛼 production and
upregulation of cell surface markers expression compared to
NoV VLPs alone. Moreover, the exposure of RAW cells to
GII.4 VLPs caused downregulation of MHC II expression,
which was corrected by addition of VP6. Finally, our results
identify themechanisms of VP6 adjuvant action in vitro. VP6
nanotubes activate andmature APCs and increase the uptake
of NoV VLPs by the APC.
5. Conclusions
In the present study, we show that recombinant RV inner core
capsid VP6 nanotubes are efficiently internalized by profes-
sional APCs probably by a clathrin-independent endocytosis
pathway involving cholesterol-rich lipid rafts, but likely other
internalization routes are also involved. Moreover, VP6 nan-
otubes efficiently activate and mature macrophages and DCs
as shown by upregulation of costimulatory molecules and
MHC II expression and release of inflammatory mediators
such as TNF-𝛼, thus augmenting the action of cells of
both innate and adaptive immune system. Furthermore, VP6
nanotubes facilitate the APC uptake of codelivered antigen,
NoV GII.4 VLPs. These results provide insights into the
mechanism of adjuvant action of VP6 nanotubes and confirm
the immunostimulatory and immunomodulatory potential
of VP6 observed in vivo.
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